Acute profound thrombocytopenia with second exposure to eptifibatide associated with a strong antibody reaction.
We present a case of eptifibatide-induced acute profound thrombocytopenia in a 64-year-old male receiving eptifibatide for the second time during percutaneous coronary intervention. Although rare, short and self-limited episodes of acute and profound thrombocytopenia have been associated with eptifibatide exposure. The thrombocytopenia is thought to be immune mediated, and assays are available to test for eptifibatide-induced platelet antibodies.
Attaya
Shariff
S
Department of Medicine, Case Western Reserve University and University Hospitals of Cleveland, Cleveland, Ohio, USA.
Kanthi
Yogendra
Y
Aster
Richard
R
McCrae
Keith
K
D000917:Antibody Formation / Q000276:immunology*; D003327:Coronary Disease / Q000188:drug therapy / Q000601:surgery; D000077542:Eptifibatide; D006801:Humans; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000009:adverse effects* / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D010976:Platelet Count; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors / Q000276:immunology*; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology
D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077542:Eptifibatide